Objective To examine preferences for follow-up testing in women screened with high or intermediate risk for Down syndrome in the first or second trimester.
Introduction
The availability and perceived benefits of non-invasive prenatal testing (NIPT) has resulted in increasing popularity amongst pregnant women seeking to avoid the risk of a diagnostic procedure-related loss. [1] [2] [3] [4] [5] NIPT can now be used as a secondary test to reduce the need for an invasive test in women with pregnancies screened as being at high risk of Down syndrome, or as an alternative to the traditional first-or second-trimester screening test. NIPT has resulted in almost a 30% reduction in the number of invasive tests performed in Hong Kong, 6, 7 which is similar to the reduction reported in other centres. [8] [9] [10] Other factors that influence women's decisions include the procedure-to-result interval, the number of abnormalities assessed, the procedure-related loss rate, and the ability to pay. Although several studies have examined women's choices between invasive tests and NIPT, they were based on hypothetical scenarios or were observational studies with common disadvantages. [5] [6] [7] [8] [9] [10] [11] Women had to choose between NIPT and an invasive test plus karyotyping, without the option of chromosomal microarray (CMA). Furthermore, the rate of procedure-related fetal loss was either not mentioned or was quoted to be 0.5% or higher. [6] [7] [8] [9] Procedure loss rates have been significantly reduced from 0.5-1.0% to 0.1-0.2%, however, 12, 13 whereas a Danish multicentre study indicated that invasive tests were not associated with an increased risk of miscarriage or stillbirth. [14] [15] [16] Both CMA and NIPT results are available in 4-7 days, compared with 14 days for karyotyping. An advantage of CMA is the ability to detect a small and wider range of submicroscopic chromosomal aberration that neither karyotyping nor NIPT can routinely detect. [17] [18] [19] The American College of Obstetricians and Gynecologists (ACOG) guideline recommended that CMA should be available to women undergoing invasive diagnostic testing for any indication, as approximately 1.7% of those with a normal ultrasound examination result and a normal karyotype had pathogenic or likely pathogenic copy number variants. 17 Equally, not all chromosomal aberrations in fetuses with nuchal translucency (NT) of ≥3.5 mm are detectable by NIPT. 20, 21 Previous studies indicated that Chinese women preferred detailed genetic results and would accept a procedure loss rate of up to 0.5%. 22, 23 Whether women favour additional genetic information provided by CMA in preference to fetal safety provided by NIPT, once advised of the lower procedure loss rates, remains unknown. The objective of this study was to examine women's preferences between NIPT and CMA when their pregnancy was screened as being at high risk for Down syndrome, and when advised that the invasive test carries 0.1-0.2% risk of procedure loss. The secondary objectives of the study were to determine the uptake of NIPT in women with intermediate risk, and to determine the perinatal outcomes in women who participated in the study.
Methods

Participants
This was a prospective multicentre cohort study conducted between July 2015 and April 2016 in three public hospitals that offer a publicly funded first-or second-trimester screening test for Down syndrome within the Hong Kong Hospital Authority Down syndrome screening program. 24 Women were provided with leaflets at booking and prior to screening that described Down syndrome, the screening options, the follow-up testing options should their pregnancy be considered high risk (HR) and if they opted not to participate in the study, and the follow-up options for those with HR or intermediate risk (IR) available within the study, as shown in Figure 1 . Video counselling on the day of screening repeated the information provided within the leaflets prior to obtaining consent to undertake screening. Women with an adjusted term risk for Down syndrome of 1:251 or higher were classified as HR, whereas women with a risk between 1:251 and 1:1200 were regarded as IR. Women classed as HR or IR who wished to have further follow-up testing after counselling were invited to participate in the study. Three contact attempts were made over a 3-week period to see whether women classed as HR or IR wished to participate in the study. Women were lost to follow-up if they remained uncontactable after the three attempts. Women could decide not to participate and continue with the existing management protocol. Under the current hospital protocol, women screened as HR are given the option to decline further testing, to undergo a publicly funded diagnostic procedure in conjunction with karyotyping, or to have self-financed NIPT after counselling. Women with classed as IR receive no additional testing unless structural abnormalities were detected at the mid-trimester morphology scan.
Women under the age of 18 years, women who were unable to provide consent, women carrying multiple or non-viable pregnancies, or carrying fetuses with structural abnormalities or hydrops at the time of Down screening, and women who had already undergone private selffinanced NIPT were excluded from the study. Women carrying fetuses with structural abnormalities or hydrops were counselled to undergo an invasive test because of the increased risk of chromosomal abnormalities or other copy number variants (CNVs). Women with NT ≥ 3.5 mm were counselled that the risk of pathogenic CNVs was 1.4%, based on previous studies. 18, 21, 25 Figure 1. Flowchart summary of the screening pathway and options provided to women before screening. After determining the risk for Down syndrome, women decided whether to take part in the study or to continue to be managed according to pre-existing hospital authority protocol.
Pregnancy and perinatal outcomes were traced from the hospital electronic records. Women who did not deliver in one of the three units were contacted by phone for their pregnancy outcomes.
Counselling
Counselling was standardised according to the individual women's adjusted risk, and was provided by specialist nurses or fetal maternal specialists, as summarised in Table 1 . During one-to-one counselling women were reinformed of their follow-up options and their questions were answered. Women classed as HR were given the option of a diagnostic chorionic villus sampling (CVS) or amniocentesis in conjunction with an in-house single nucleotide polymorphism (SNP) microarray (FetalDNAChip), or to have a secondary NIPT screening test using SafeT21Express (Xcelom Limited, Hong Kong). The CMA was a genome wide targeted diagnostic test for CNVs, which could detect 100 specific microdeletion or microduplication syndromes as well as uniparental isodisomies. Women undergoing CMA had pre-test counselling, with the possibilities of variants of unknown significance (VOUS) explained. Women were counselled that the procedure-related miscarriage risk was 0.1-0.2% based on our local data and meta-analyses, 14, 15, 26, 27 and that the SafeT21Express NIPT test carried no risk of miscarriage. NIPT could detect 99.5, 99, and 95% of trisomies 21, 18 and 13, respectively, as well as 95% of sex chromosome aneuploidies, but could not detect submicroscopic CNVs, unlike CMA. Women were informed that results would be available in 5-7 days, and that they would not need to pay. Women with IR were offered the option of having the same NIPT as women with HR. Reasons for declining the offer of NIPT were documented, and all women with HR were advised that NIPT results would need to be confirmed by prenatal diagnosis using invasive testing, as almost 1% of NIPT results are false positives. Further counselling was offered to women with non-reportable results or incidental findings of chromosomal abnormalities other than trisomy 13, 18 and 21, and sex-chromosome aneuploidy, with the option to undergo a diagnostic test. In women who underwent diagnostic testing, CMA with pathogenic CNVs or VOUS were discussed within the prenatal diagnostic team, and counselling was provided to parents by a fetal medicine specialist. A referral to a clinical geneticist was made, if necessary.
Sample size
The three hospitals combined perform 16 000 first-or second-trimester screening tests per year for Down syndrome, 5 and 10% of which, respectively, have an adjusted term risk that falls within the HR and IR ranges. It was estimated that a minimum sample size of 260 women was needed from the HR group to estimate that 50% of women would chose NIPT with a maximum 95% confidence interval (95% CI) of AE5%, on the assumption that women with HR preferred NIPT or CMA equally. A minimum sample size of 310 women was required from the IR group to estimate that 50% of women would elect to undergo an additional screening test for additional reassurance. 
Results
During the study period 10 348 women with a singleton pregnancy underwent screening for Down syndrome at the three hospitals, 9463 (91.4%) of whom had a first-trimester screening test. The mean maternal age was 32.4 years (standard deviation, SD = 4.5 years), 2622 (25.3%) were ≥35 years of age at delivery, 5185 (50.1%) were nulliparous, 9139 (88.3%) had a spontaneously conceived pregnancy, and 9276 (89.6%) were ethnically Chinese. There were no statistically significant differences in pregnancy or sociodemographic factors between those who had HR or IR except for age. The HR group contained a significantly greater proportion of women who were ≥35 years of age at delivery (57.9 versus 50.7%; P = 0.03). Four hundred and fifty-three (4.4%) women screened were HR, 347 (76.6%) of whom participated in the study. The remaining 106 (23.4%) women with HR were excluded or elected not to participate: 16 (3.5%) had ultrasounddetected structural abnormalities and 90 (19.9%) disclosed that they had already had self-financed NIPT or would seek additional antenatal care from a private specialist. Pregnancy or sociodemographic factors available at the time of the Down syndrome screening between those who did and those who did not opt to participate in the study were not statistically significant with regards to age, parity and adjusted term risk for Down syndrome (P > 0.05 for all).
Eight hundred and fifty-three (8.2%) women were regarded as IR, 614 (72%) of whom participated in the study. Of the 239 who did not participate in the study, 74 (8.7%) had already received self-financed NIPT from a private specialist, and 165 (19.3%) had abnormal ultrasound findings, were unable to give informed consent, or were lost to follow-up. Pregnancy or sociodemographic factors available at the time of screening for Down syndrome did not statistically differ with regards to age, parity, and adjusted term risk of Down syndrome (P > 0.05 for all) between those who did and did not opt to participate in the study.
The maternal and pregnancy characteristics of the 347 women with HR and 614 women with IR who participated are reported in Table 2 . Table 3 reports the pregnancy aneuploidy detected in the women with HR and IR. Only two (0.3%) out of 723 NIPT tests performed had a non-reportable result: in both cases the women opted for an invasive test that was reported as euploidy.
CMA or NIPT amongst women with HR
Two hundred and sixteen (62.2%) women opted for NIPT and 128 (36.9%) women opted for CMA. Three women (0.9%) declined all further testing. There were no procedure-related fetal losses. There was no significant difference in maternal age, nulliparity, mode of conception, education level, and religious belief between women who opted for NIPT and women who opted for CMA (P > 0.05 for all). Multivariate logistic regression analysis indicated that the only significant factors found to be associated with a woman's choice were their level of risk and the thickness of NT (Table S1 ). Women were significantly more likely (adjusted odds ratio, aOR = 1.93; 95% CI 1.02-3.65) to choose CMA if their risk for Down syndrome was between 1:2 and 1:9, compared with those with a risk between 1:10 and 1:250. Women with an NT of ≥3.5 mm were more likely to opt for CMA (aOR 2.92; 95% CI 1.07-8.02). Onequarter of women with a thickened NT (≥3.5 mm) opted for NIPT and not CMA, despite being informed during counselling that 1.4% of fetuses had pathogenic CNVs.
NIPT amongst women with IR
Five hundred and seven (84.2%) women opted for NIPT, whereas the remaining 107 women (17.4%) declined further testing either because they considered themselves as low risk (n = 104) or would not terminate their pregnancy even if their pregnancy was affected by Down syndrome. There was no significant difference in maternal age, nulliparity, mode of conception, education level, and religious belief between women who did and did not opt for NIPT (P > 0.05 for all).
There was one true positive and one false negative case of Down syndrome. The karyotype of cord blood taken after birth showed 46,XX,idic(21)(q22.3), whereas placental tissue DNA analysis indicted both monosomy and Down syndrome cell lines. The presence of two cell lines in the placenta balancing each other resulted in the NIPT counting method being unable to detect the presence of extra chromosome 21. To date the published cases of 'mirror image' duplication of chromosome 21 in the literature would suggest that this is a rare and sporadic mutational event. [28] [29] [30] [31] There were two cases of trisomy 18, only one of which was correctly identified by NIPT; the second case was missed by NIPT but was suspected at the mid-trimester morphology scan because of multiple trisomic features, and this was confirmed through amniocentesis. Overall, for the detection of common aneuploidies, NIPT as a secondary test in the IR group detected one additional case of trisomy 18 and Down syndrome, but also missed one case of trisomy 18 and Down syndrome.
Discussion
Main findings
This is the only study comparing the choice between CMA and NIPT in women screened as HR for aneuploidies. Nearly all women with HR opted for follow-up testing. In a setting where both the costs and the time to report results are the same, approximately 60% opted for NIPT as Values are expressed as means AE SDs or n (%).
a secondary screening for common aneuploidies only, and 40% chose to undergo invasive tests provided that it was accompanied by CMA yielding additional information. The main factors that determined choice of CMA over NIPT was thick NT and adjusted term risk of ≥1:9. Twenty-five percent of women with an NT of ≥3.5 mm opted for NIPT, despite counselling that 1.4% of pregnancies had pathogenic CNVs. In the IR group, 84.2% women opted for NIPT as a secondary test.
Strengths and limitations
The strengths of this study were that the ability to pay and the procedure-to-result interval were not confounding factors in making the decision. The only factor considered was fetal safety, with some uncertainty over obtaining a more definitive genetic result. Women with pregnancies with fetal structural abnormalities were excluded because of the increased chance of being associated with CNVs, which NIPT was unable to detect. A limitation was the homogeneity of our study population, with the majority being Chinese, and thus these results may not be generalisable to all. Secondly, cost-effectiveness analysis was not performed as the healthcare costs for an individual with Down syndrome in Hong Kong is unknown. Our only option would be using costs estimated in other countries, which are inconsistent.
32,33
Interpretation
Our study showed that almost 60% of women with HR chose NIPT in favour of fetal safety, and almost 40% preferred invasive tests for CMA, yielding more genetic information, once advised of the lower procedure-related fetal loss rates. Previous studies indicated that Chinese women would accept a procedure-related loss risk of up to 0.5%, and placed a greater value on knowing more rather than less information when making their decisions. 22, 34 Offering routine CMA instead of karyotyping would provide women with faster reporting times, and allow nearly 40% of women in our case to obtain additional genetic information that karyotyping is unable to provide. One challenge would be in counselling women with a fetus reported to have VOUS about CMA. The importance of both pre-and post-test counselling in the prenatal setting must be emphasised. The almost 100% rate of follow-up testing could be explained by the lack of acceptance of the birth of an 'abnormal' baby in Chinese culture. This is also reflected by the fact that a substantial proportion of women (19.9% in the HR group and 8.7% in the IR group) had self-financed NIPT from a private specialist before they attended their first-or second-trimester screening test offered in public hospitals. Median utility scores for the acceptance of the birth of a baby with Down syndrome were nearly three times lower than that of the procedure loss (0.2 versus 0.55). 23 This contrasts with utility scores of 0.81 versus 0.92 and 0.65 versus 0.78 for the same respective outcomes in a non-Chinese population. 35 Chinese couples have expressed disappointment, guilt, self-blame, shame, and social stigma upon the birth of a disabled child. [36] [37] [38] Maternal anxiety and a desire to avoid the birth of a child with a detectable disability could also explain why nearly one in five women undergoing a conventional screening test disclosed that they had already had NIPT during counselling. The recent study by Norton et al. 39 highlighted that NIPT, although good, is not perfect, and that fetuses with Down syndrome missed by NIPT were detected using the conventional screening test. The recent meta-analysis by Taylor-Phillips et al. reported a lower accuracy of NIPT, with only a 97% detection rate of Down syndrome, compared with the detection rate estimated by Gil et al. 40, 41 Furthermore, a reassessment of the Noninvasive Examination of trisomy (NEXT) study indicated that when indeterminate results were classified as negatives, NIPT sensitivity would be reduced from an initially perfect 100% to a much lower 93%. 39 It is anticipated that the recent evidence showing a drop in NIPT detection rates would potentially further alter Chinese women's decisions. In an earlier study, 25% of women indicated that they would only accept NIPT as a secondary screening test for Down syndrome if the detection rate was >98%. 11 In future women may have to decide between a loss rate of 0.1-0.2% versus a 3% false-negative rate of NIPT, based on the metaanalysis by Taylor-Phillips. 40 To date there have been only two published prospective studies in women screened as HR that assessed the women's choice between invasive testing (karyotyping) and NIPT as a secondary test. 42, 43 Similar to our study, Gil et al. 42 reported that 60% of women with a first-trimester gestation specific risk of 1:100 or higher (term risk of 1:145 or higher) opted for NIPT, 38% opted for invasive testing, and only 2% declined further testing. In women with IR (1 in 101-2500; term risk of 1 in 146-3600), 92% proceeded to NIPT as a secondary test. Chitty et al. 43 reported higher NIPT uptake rates (74%) and lower invasive test rates (18%) in women with HR, whereas 80% of women with IR opted for NIPT, similar to our study. Chitty et al. 43 postulated that if NIPT was offered as a secondary screening test, then an additional 195 fetuses with Down syndrome would be detected per year, that there would be 3368 fewer invasive tests, and that the overall service provision costs were not increased within a contingent healthcare model in the UK. The additional fetuses with Down syndrome detected in their study would be from the group who previously declined invasive tests. Offering NIPT as a secondary test in our locality would not be expected to result in the detection of additional fetuses with Down syndrome, as the followup test rate is already high, and the procedure loss rates are already low and similar to the spontaneous miscarriage rate amongst women who did not have any invasive procedures during their pregnancy. 15 The availability of publicly funded NIPT resulted in the proportion of women declining testing falling from 4 to <1% in our current study. Women's preference between these two tests is important with regards to maximising the use of resources, service planning, and the continued development of prenatal diagnostic testing services offered within public healthcare models, especially when CMA costs are now similar to that of cytogenetic testing and are lower than that of NIPT. 44 
Conclusion
In conclusion, 62% of women screened as HR for Down syndrome would opt for NIPT as a secondary screening test, whereas 37% would still proceed to have an invasive test with CMA. Very few (0.9%) would decline further testing. Offering NIPT as secondary screening would lead to just a marginal increase in the detection of Down syndrome in Hong Kong, as follow-up rates are already approaching 100%. Further studies in different populations on choice between CMA and NIPT would be beneficial in understanding women's choice, future screening strategy, and service planning. Table S1 . Multivariate logistic regression analysis to determine significant factors influencing choice for chromosomal microarray in preference to non-invasive prenatal testing in women screened as being at high risk for Down syndrome. &
